Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26696945 | 0.81 | RXFP1 (0.40) | MEN1KMT2ANPC1RAB9ARXFP1 | |
| SCHEMBL23281864 | 0.80 | AAK1 (0.37) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL5367134 | 0.79 | RXFP1 (0.50) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL30218670 | 0.79 | MAPT (0.42) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL27357005 | 0.78 | MAPT (0.57) | MEN1KMT2AMAPTSMN1; SMN2TP53 | |
| SCHEMBL1037516 | 0.77 | NR4A2 (0.50) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL632629 | 0.75 | PDK1 (0.54) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL30976363 | 0.75 | PDK1 (0.54) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL30341113 | 0.75 | MEN1 (0.46) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL14243354 | 0.75 | NPC1 (0.46) | MEN1KMT2ANPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-4129406-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | MEN1 859/4885KMT2A 3130/4885NPC1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.